Clinical Trials · NCT01240629
Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
- Phase
- Phase 1/Phase 2
- Recruitment status
- Completed
- Sponsor
- University of Southern California
- Enrollment
- 43
- Start date
- Nov 2010
- Locations
- 1 site, United States
- Primary endpoint
- Clinical benefit defined as non-progression with no dose-limiting toxicity or other toxicity requiring termination of treatment